A Single Injection of Pegylated Murine Megakaryocyte Growth and Development Factor (MGDF) Into Mice Is Sufficient to Produce a Profound Stimulation of Megakaryocyte Frequency, Size, and Ploidization

By Julie T. Arnold, Najat C. Daw, Paula E. Stenberg, Deepthi Jayawardene, Deo Kumar Srivastava,

and Carl W. Jackson

Despite numerous studies investigating the action of c-mpl ligand, no reports have defined the in vivo changes in megakaryocytopoiesis in response to a single injection of this cytokine. Here we compare the kinetics of the megakaryocytopoietic response in C57BI/6J mice administered 25 μ g/ kg or 250 μ g/kg of pegylated (PEG) murine megakaryocyte growth and development factor (MGDF) as a single intravenous injection. Megakaryocytes of mice treated with MGDF had normal ultrastructure, showing a typical distribution of the demarcation membrane system, α -granules, and other cytoplasmic organelles. Megakaryocyte ploidy, size, and frequency were markedly increased with both MGDF doses. Megakaryocyte ploidy was maximally increased from a modal value of 16N to 64N on day 3, with both doses of MGDF. Similarly, a comparable increase in megakaryocyte size occurred in the two MGDF groups. Increased megakaryocyte size was coupled to the increase in megakaryocyte ploidy, and no evidence for independent regulation of mega-

THE RECENT purification and cloning of the c-*mpl* ligand¹ or thrombopoietin (TPO),²⁻⁴ and the production of recombinant forms such as megakaryocyte growth and development factor (MGDF),⁵ have provided the opportunity to unambiguously define the regulatory effects of this cytokine on megakaryocytopoiesis. Reports on this cytokine, have described its ability to cause a profound increase in circulating platelet levels in mice,^{1.2.6} rats,⁴ and nonhuman primates,^{7.8} presumably as a result of expansion of the megakaryocyte progenitor population^{7.9-12} and enhanced megakaryocyte maturation.^{4,8,10,12}

In vitro studies have shown that *c-mpl* ligand is capable of inducing megakaryocyte colony formation and augmenting megakaryocyte maturation. *c-mpl* ligand has been shown to specifically induce colony-forming unit-megakaryocyte (CFU-Meg) formation from unfractionated murine bone marrow (BM) cells,^{10,13} murine fetal liver cells,¹⁴ and from human peripheral blood (PB) or BM CD34⁺ cells.^{11,12,15-17} Addition of *c-mpl* ligand to human megakaryocytes in culture can increase platelet-specific antigens,^{1,5} increase megakaryocyte to develop into morphologically normal, mature megakaryocytes capable of forming proplatelet processes.¹⁸ However, the actual process of proplatelet formation appears to be inhibited by the presence of *c-mpl* ligand in the culture medium.¹⁹

In vivo, daily administration of *c-mpl* ligand to mice caused an increase in de novo platelet synthesis, as determined by ³⁵S incorporation into platelets,¹ and resulted in the circulating platelet count being increased to three to four times the baseline values.^{2,20} In nonhuman primates, daily administration of MGDF raised the platelet count threefold within 5 to 7 days^{7,8} as a result of increases in megakaryocyte progenitors,⁷ megakaryocyte numbers, volume, and ploidy.⁸

In various models of myelosuppression, daily administration of MGDF or thrombopoietin is able to enhance recovery karyocyte size within individual ploidy classes was apparent. In contrast to megakaryocyte ploidy and size, the increase in megakaryocyte frequency was markedly different with the two doses of MGDF. The proportion of 2N and 4N cells was increased from a baseline of 0.035% to 0.430% by day 4 in mice treated with the higher dose of MGDF, but only to 0.175% in mice administered 25 μ g/kg of MGDF. The marked increase in the pool of these immature megakaryocytes translated to a sustained elevation in the frequency of polyploid megakaryocytes (8N cells and greater). In contrast to the sustained increase in the frequency of polyploid cells, the level of polyploidization was downregulated on days 6 to 10, but normalized by day 14. We conclude that a single injection of MGDF is able to expand the megakaryocytic pool in a dose-dependent manner, which, with subsequent maturation, should lead to an increased rate of platelet production.

© 1997 by The American Society of Hematology.

from thrombocytopenia^{6,20} and reduce mortality.⁶ The ability of thrombopoietin to enhance platelet recovery in myeloablative models has varied. Some studies report an accelerated recovery of platelet numbers in animals administered thrombopoietin after BM or PB progenitor cell transplantation,^{21,22} whereas others have not observed this effect.^{23,24} If, however, lethally irradiated recipients were transplanted with marrow collected from animals pretreated with thrombopoietin, the thrombocytopenia in the transplanted animals was less marked and shorter in duration.²³ Similarly, irradiated mice receiving PB progenitor cells (PBPC) mobilized by pegylated MGDF²² were thrombocytopenic for fewer days, compared with recipients of unmobilized PBPC.

In all but one study,²⁰ MGDF or thrombopoietin has been administered on a daily injection schedule, ranging in duration from 2 to 10 days,^{2,4,6,7,20} to 4 weeks.⁸ The choice of a daily injection schedule has been based on the use of other hematopoietic cytokines²⁵⁻²⁷ rather than the pharmacokinet-

From the Division of Experimental Hematology and the Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; and the Department of Pathology, Oregon Health Sciences University, Portland.

Submitted June 5, 1996; accepted September 3, 1996.

Supported in part by P30CA21765 Cancer Center Support Grant and P01CA201180 from the National Cancer Institute, Public Health Service, Department of Health and Human Services, and by American Lebanese Syrian Associated Charities.

Address reprint requests to Carl W. Jackson, PhD, Division of Experimental Hematology, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

^{© 1997} by The American Society of Hematology. 0006-4971/97/8903-0025\$3.00/0

ics of thrombopoietin. More importantly, no detailed analysis of the in vivo kinetics of megakaryocytopoiesis in response to a single administrative dose has been reported. To address this issue and with the rationale that an understanding of megakaryocyte kinetics would aid the design of a clinically effective administration schedule, we have defined the megakaryocytic response in C57B1/6J mice administered a single intravenous injection of pegylated recombinant murine MGDF (PEG-rmMGDF).

MATERIALS AND METHODS

Young adult C57Bl/6J male mice were purchased from The Jackson Laboratories (Bar Harbor, ME) and ranged between 10 and 20 weeks of age at the time of study.

PEG-rmMGDF was kindly supplied by Amgen Inc (Thousand Oaks, CA). The stock solution of PEG-rmMGDF (usually 0.63 mg/mL) was diluted with 1% normal (homologous) mouse serum (NMS) in phosphate-buffered saline (PBS) on the day of administration. A standard 2.5 μ g/mL and 25 μ g/mL solution of rmMGDF was made for injection at the 25- μ g/kg and 250- μ g/kg doses, respectively. Each mouse received 0.1 mL per 10 g body weight, whereas control mice received an equivalent volume of 1% NMS. MGDF or carrier were administered intravenously via the lateral tail vein on day 0, after inducing vasodilation by warming the mice for 10 to 20 minutes under an examination lamp.

Flow cytometric analysis of megakaryocytes. Mice were anesthetized with methoxyflurane and killed by exsanguination at frequent intervals from 12 hours to 14 days after MGDF administration. Marrow from one femur and one tibia was flushed into 2 mL of CATCH medium²⁸ containing 8 μ mol/L prostaglandin-E₁ (PGE₁) (Sigma, St Louis, MO). Marrow cells were gently resuspended with a plastic, standard-bulb transfer pipette (Fisher, St Louis, MO) and kept on ice. Marrow suspensions were filtered through 105- μ m monofilament nylon mesh (Small Parts Inc, Miami, FL) to remove cell clumps and debris. The cells were pelleted at 400g for 5 minutes at room temperature (RT), and then resuspended in 1 mL of CATCH diluted 1:1 with PBS containing 5% normal goat serum (NGS) (GIBCO-BRL, Life Technologies Inc, Grand Island, NY). NGS was used to block nonspecific binding of goat-derived secondary antibody.

Megakaryocytes were labeled for 60 minutes on ice with a saturating concentration of a rat monoclonal antibody to mouse platelets (4A5), and shown to have a high specificity for murine megakaryocytes²⁹ (kindly provided by Dr S. Burstein, University of Oklahoma, Oklahoma City). Cells were pelleted at 400g for 5 minutes at RT and resuspended in 1 mL of CATCH diluted 1:1 with PBS containing 5% NGS. The megakaryocyte-bound 4A5 antibody was indirectly fluoresceinated with fluorescein isothiocyanate (FITC)-goat anti-rat IgG F(ab')₂ (Biosource, Camarillo, CA) for 30 minutes on ice. Marrow cells labelled with only FITC-goat anti-rat IgG F(ab')₂ served as the negative control. In MGDF-treated animals, an increased concentration of 4A5 and FITC-labeled second antibody was added to the samples when megakaryocyte frequency and size were increased to ensure saturation of 4A5 binding sites, as monitored by the level of green fluorescence.

After labeling with primary and secondary antibody, the cells were pelleted by centrifugation at 400g for 5 minutes at RT, and resuspended in 2 mL of hypotonic propidium iodide (50 μ g/mL in 0.1% sodium citrate).³⁰ Before flow cytometric analysis, the cells were treated with RNAase (50 μ g/mL, bovine pancreas; Calibiochem Corp, San Diego, CA), and filtered through 105- μ m nylon mesh.

DNA content of 4A5-positive cells was analyzed by two-color flow cytometry³¹ on a FACScan (Becton-Dickinson, San Jose, CA). DNA contents of all 4A5-positive cells were measured (DNA contents 2N-128N). 4A5 positivity was defined by setting the horizontal (FL-1, green fluorescence) window at a level to minimize 6N events. We have previously shown³¹ that most all 6N events are aggregates of other marrow cells and thus serve as an internal negative control for the green window selection. Marrow cells from control animals were always used to set this gate and the same gate used to define 4A5-positive cells in marrow from MGDF-treated animals. This level of green fluorescence was associated specifically with 4A5binding, as marrow labeled with FITC-second antibody alone showed few if any cells in the defined 4A5-positive window. The proportion of cells in each ploidy class was determined by integrating the number of cells under each DNA peak. Megakaryocyte frequency was calculated from the flow cytometric profiles as the percentage of cells expressing 4A5. Cell size was indexed by forward-angle light-scatter (FSC) and the mean megakaryocyte size of polyploid cells was determined from the two-color profile.

Collection and preparation of BM for transmission electron microscopy. Mice were killed 4 days after administration of 25 μ g/ kg, 250 µg/kg rmMGDF, or 1% NMS. BM was gently flushed from the tibia of each mouse into 2 mL of fixative composed of 1.5% glutaraldehyde + 1.5% paraformaldehyde in 0.1 mol/L sodium cacodylate buffer, pH 7.4. Two-percent dimethyl sulfoxide (DMSO) was added, and samples promptly microwaved for 10 seconds and fixed overnight at 4°C. The marrow was rinsed in 0.1 mol/L sodium cacodylate buffer, pH 7.4, and then postfixed in 2% osmium tetroxide in 0.1 mol/L sodium cacodylate buffer for 1.5 hours. The samples were dehydrated through a series of graded ethanol, infiltrated with toluene and subsequently with resin composed of DDSA, NMA, and DMP-30 (Ted Pella, Redding, CA) and LX-112 (Ladd Research Industries, Burlington, VT), and finally embedded in 100% of the above resin. Thin sections were cut and stained with uranyl acetate and lead citrate and viewed with a Philips 301 transmission electron microscope (Philips Electronic Instruments, Inc, Mahwah, NJ).

Statistical analyses. Statistical comparison of megakaryocyte ploidy distributions is complex and previous studies performed on megakaryocyte ploidy have either neglected to report statistics, compared the proportion of cells in each class using univariate twosample t^{32} or Mann-Whitney rank sum³³⁻³⁸ test, or used a summary statistic of all ploidy classes, such as the geometric mean,³⁹ again compared using univariate test procedures.4,40,41 However, these approaches do not consider that the proportion of cells in each of the DNA classes are interrelated. A more appropriate procedure, and one we have implemented in our studies, is the Hotelling's T² test,⁴² which is a multivariate test procedure for comparing two population mean vectors and takes into account the underlying covariance structure. This allowed us to analyze megakaryocyte ploidy by comparing the distribution (all DNA classes simultaneously) in the control group and the distribution at each of the time points for each MGDF dosage. Hotelling's T² test is appropriate if the underlying distribution function for the two populations can be assumed to be multivariate normal. However, due to the relatively small sample sizes of our data, we did not wish to make this assumption, and therefore used a Permutation test⁴³ of Hotelling's T² to evaluate the differences in the ploidy distributions. The following is an example of how the data were analyzed using the permutation/Hotelling's T² test. For comparison of the ploidy distributions for the control group (13 mice) and the group of mice killed 12 hours after the administration of 25 μ g/kg of rmMGDF (5 mice), we first obtained the value of Hotelling's T² statistic for the original sample and denoted it by T_{0}^{2} . The Hotelling's T^{2} statistic was then calculated for all possible samples that could be obtained by allocating 13 of the 18 mice into the control group and the remainder to the treatment group. The total number of permutations for this Hotelling's T² test was 8,568. The P value was obtained by counting the number of times we observed a value of T^2 greater than T_0^2 and dividing it by the total number of permutations (8,568). When the total number of permutations was less than 17,000 for a particular comparison, then all the possible permutations were used in obtaining the P value (a permutation test by exact methods). If not, a random sample (Monte Carlo modication) of 17,000 permutations was chosen to obtain the P value. With 17,000 permutations, we were assured that the estimated P value would be within a 1% margin of error of the true Pvalue with 99% confidence.44 A program was written in MINITAB45 (MINITAB, Inc, PWS-KENT Publishing Co, Boston, MA) to calculate Hotelling's T² and implement the permutation test. Because 13 multiple comparisons were made (comparing ploidy distribution at each time point to the control), a Bonferroni correction⁴⁶ was used to maintain the overall experimental type I error level of $\alpha = .05$ (a 95% confidence limit of detecting a real difference when there is one). Therefore, in each comparison the observed P value had to be less than .004 (.05/13) to be judged significant. Type I error is the probability of rejecting the null hypothesis and concluding that there is a significant difference between the two groups when in fact there is none.

The effect of MGDF treatment with time on megakaryocyte frequency (of both 2N/4N and 8N-128N cells) and size in mice treated with 25 μ g/kg and 250 μ g/kg rmMGDF was analyzed using the Kruskal-Wallis test,47 a nonparametric test procedure. Once an effect of rmMGDF on a given megakaryocyte parameter was detected, a posthoc analysis comparing the control group to all other (13) time points was done using Wilcoxon-Mann-Whitney rank sum test.47 Because of the small sample sizes, the permutation test as implemented in the statistical software package STATXACT⁴⁸ (CYTEL Software Corp, Cambridge, MA) was used. When the total number of permutations was large, the Monte Carlo estimate of the P value was based on 10,000 permutations. With 10,000 permutations, we can be 99% confident that the estimated *P* value will be within 1.3% margin of error of the true P value. Once again the Bonferroni correction was used so that the posthoc comparisons were performed at level where the P value had to be less than .004 (.05/13) to be significant.

All results are graphed showing the arithmetic mean \pm standard error of the mean (SEM), although most of the statistical procedures used are nonparametric in nature and involve comparison of medians rather than means.

RESULTS

Megakaryocyte ploidy. The DNA ploidy classes were well resolved by the flow cytometric method at all time points after MGDF administration. This is illustrated in Fig 1, where representative DNA content distributions are shown for the two extremes of response (maximal stimulation and downregulation) to MGDF. Mean histograms derived from the results of individual flow cytometric profiles of DNA content are presented in Fig 2.

The modal polyploid DNA class for control C57B1/6J mouse megakaryocytes was 16N (Fig 2); approximately two thirds of the polyploid megakaryocyte population were 16N, with 10% 8N, and 20% 32N. Less than 3% of cells had a DNA content of 64N or greater (Fig 2). A significantly altered polyploid distribution was observed from 12 hours until day 9 (25 μ g/kg) or day 10 (250 μ g/kg), following administration of a single injection of MGDF. An increase in megakaryocyte ploidy was detected as early as 12 hours, and the response was evident with both doses of MGDF ($P \leq .002$ for both doses, based on permutation/Hotelling T² test) (Fig 2). The combined relative frequency of 64N and



Fig 1. Representative megakaryocyte DNA distributions from the BM of individual mice given 1% mouse serum (A), or treated with 25 μ g/kg rmMGDF and killed on day 3 (B) or day 6 (C).

128N cells at 12 hours had increased from 3.0% to 12.0% (both doses), with a corresponding decrease of 16N cells, whereas the 32N frequency remained relatively unchanged. By 24 hours, the modal ploidy class was increased to 32N in mice administered 250 μ g/kg of MGDF. 16N remained modal with the lower dose of MGDF; however, the relative frequency of 32N cells was approximately doubled from control values. By 36 hours, the modal megakaryocyte ploidy class had increased to 32N, in mice treated with either dose of MGDF, when the 32N cells represented over 50% of the polyploid population. The 64N and 128N cells comprised 20%, and the 8N and 16N cells less than 30%. The ploidy of the megakaryocytes continued to increase over the next



Fig 2. Effects of a single intravenous injection of rmMGDF on megakaryocyte ploidy distributions in mice treated with 25 μ g/kg (III) or 250 μ g/kg (III) MGDF. Megakaryocyte ploidy distributions were significantly different from the control distribution from 12 hours to day 9 in mice treated with 25 μ g/kg of MGDF, and from 12 hours to day 10 in mice treated with 250 μ g/kg of MGDF. From 387 to 1,136 (median 871) 4A5 positive cells with DNA contents \geq 8N were analyzed per mouse. Each distribution shows the mean \pm SEM of each megakaryocyte ploidy class; for the 25- μ g/kg dose, n = 4-10 mice per MGDF group and n = 13 for controls; for the 250- μ g/kg dose, n = 5-9 mice per MGDF group and n = 20 for controls. Controls received 0.1 mL/10 g body weight of 1% NMS in PBS.



36 hours, and peaked at day 3, with 64N as the modal ploidy class at both MGDF doses. The relative frequency of 64N cells was slightly higher for the 250- μ g/kg dose (48%) than for the 25- μ g/kg dose (41%) and the frequency of 128N cells with the higher MGDF dose was double (13%) that of the lower dose (5%). By day 4, megakaryocyte ploidy began to shift back toward normal, where 32N was the modal ploidy with the 250- μ g/kg dose and 16N was the modal for the 25- μ g/kg dose. By day 5, the modal ploidy class had returned to 16N in mice treated with either dose of MGDF; however, the ploidy distribution remained significantly different from control (P < .0001 for both doses, permutation/ Hotelling T^2 test) due to the notable increase in the relative frequency of 8N cells. On day 6, in mice administered 25 μ g/kg of MGDF, 8N cells were three times, whereas 32N cells were one fifth, the relative frequency found in control BM (P < .0001, permutation/Hotelling T² test). On day 7, in mice administered 250 μ g/kg of MGDF, 8N cells were four times and 32N cells were one fifth the relative frequency found in control marrow (P < .0001, permutation/Hotelling T^2 test). 16N cells in both cases were only marginally below control values. These data suggest that megakaryocyte endomitosis was less stimulated in these mice and the majority of cells were not able to undergo more than three endomitotic cycles. By day 9, ploidy began to normalize in mice treated with 25 μ g/kg of MGDF, and by day 10 the relative frequency in each ploidy class was no different from that of megakaryocytes from control BM (P = .006, permutation/ Hotelling T² test). Megakaryocyte ploidy of mice receiving the higher MGDF dose showed a similar pattern, but normalization of the ploidy distribution did not occur until day 14 $(P = .408, \text{ permutation/Hotelling } T^2 \text{ test}).$

Megakaryocyte frequency. We chose to separate the megakaryocytes into two populations for frequency analysis: those with a presumed capacity for cell division, cells of 2N/4N DNA content, and those cells that had ceased dividing and were undergoing or had completed polyploidization (8N, 16N, 32N, 64N, and 128N cells). We realize that this division of cells has its limitations and is unable to discriminate the 2N cells not in cell cycle, or the 4N population that is truly polyploid, but it provides an estimate of the proliferating (2N/4N cells) versus the nonproliferating (8N-128N) megakaryocyte population.

Previous morphometric studies have estimated the frequency of morphologic recognizable megakaryocytes in normal BM to be 0.05%.³⁶ Our current study, using flow cytometric analysis, estimated that the frequency of 4A5-positive polyploid cells (presumably the morphologically recognizable megakaryocytes) to be approximately 0.08%. The combined frequency of 4A5-positive 2N and 4N cells was approximately 0.035%.

Administration of either 25 μ g/kg or 250 μ g/kg of rmMGDF had a significant effect on the frequency of 2N/4N cells (P < .0001, Kruskal-Wallis, both doses) (Fig 3A). The frequency of the 2N/4N cells in mice administered 25 μ g/kg of MGDF remained constant for 36 hours after cytokine administration (Fig 3A). At day 2, the frequency of 2N/4N cells started to increase (P = .001, Mann-Whitney); by day 4, the 2N/4N cell frequency had peaked at 0.175%, a

827



Fig 3. Effect of a single intravenous injection of rmMGDF on the frequency of (A) 2N-4N megakaryocytes and (B) 8N-128N polyploid megakaryocytes. The frequency of 2N/4N cells was significantly increased from days 2 to 4 in mice treated with 250 μ g/kg of MGDF and from days 2 to 5 in mice treated with 250 μ g/kg ofMGDF (A). The frequency of 8N-128N cells was significantly increased from days 3 to 5 in mice treated with 25 μ g/kg MGDF and from days 2 to 14 in mice treated with 250 μ g/kg MGDF (B). At 12 hours, the frequency of 8N-128N cells was significantly decreased with the 250- μ g/kg dose of MGDF (B). Each data point represents the mean \pm SEM of megakaryocyte frequency; for the 25- μ g/kg dose, n = 4-10 mice per MGDF group and n = 13 for controls and for the 250- μ g/kg dose, n = 5-9 mice per MGDF group and n = 20 for controls. Data from control mice were pooled to represent the day 0 data point.

fivefold increase from baseline values (P < .0001, Mann-Whitney). By day 5, 2N/4N frequency promptly returned to baseline values (P = .13, Mann-Whitney) and remained not significantly different from controls through to day 14. Mice administered 250 μ g/kg of MGDF showed similar kinetics in the 2N/4N frequency. The first increase was again detected on day 2 (P < .0001, Mann-Whitney), and the frequency increased to a maximum of 0.430% on day 4 (P < .0001. Mann-Whitney), representing a 10-fold increase over control values, or twice the increase observed with the $25-\mu g/kg$ dose. 2N/4N frequency sharply decreased to 0.125% on day 5, but in contrast to mice treated with the lower dose of MGDF, 2N/4N frequency was still significantly increased from baseline (P < .0001, Mann-Whitney). By day 6, 2N/ 4N frequency had normalized (P = .11, Mann-Whitney), and remained normal through to day 14.

Administration of either 25 μ g/kg or 250 μ g/kg rmMGDF

also had a significant effect on the frequency of polyploid megakaryocytes (P < .0001, Kruskal-Wallis, both doses) (Fig 3B). The frequency of polyploid megakaryocytes, 12 hours after administration of either 25 or 250 μ g/kg of MGDF, appeared to decrease, but this decrease was only found to be significant with the 250 μ g/kg dose (P = .002for 250 μ g/kg; P = .06 for 25 μ g/kg, Mann-Whitney). By day 3, the frequency of polyploid megakaryocytes was twofold of normal in mice treated with 25 μ g/kg of MGDF (P = .003, Mann-Whitney), and continued to increase, reaching a maximal frequency of 0.289% (fourfold of normal) on day 4 (P < .0001, Mann-Whitney). After this time, the frequency of polyploid megakaryocytes decreased, and although still twofold of normal by day 5 (P = .003, Mann-Whitney), it was not significantly different from control values from day 6 onward. In contrast, mice treated with 250 μ g/kg MGDF had an earlier and sustained increase in the frequency of polyploid megakaryocytes. By day 2, the frequency of polyploid megakaryocytes was increased (P = .0009, Mann-Whitney) and continued to rise to a maxima of 0.288% (fourfold of normal) on day 4 (P < .0001, Mann-Whitney). On day 5, the frequency of polyploid megakaryocytes in mice treated with 250 µg/kg of MGDF remained at fourfold of control (P < .0001, Mann-Whitney), decreased to twofold of normal by day 6 (P = .002, Mann-Whitney), and was sustained at a significantly elevated level through to day 14 $(P \leq .003, \text{Mann-Whitney}).$

Megakaryocyte size. Flow cytometric measurement of FSC is an index of cell size. In our studies, we analyzed the average FSC of polyploid megakaryocytes to assess the effect of MGDF on megakaryocyte size. The megakaryocytes sized were the same cells analyzed for ploidy and frequency.

Administration of either 25 μ g/kg or 250 μ g/kg rmMGDF significantly altered mean megakaryocyte size of 8N-128N cells (P < .0001, Kruskal-Wallis, both doses) (Fig 4), with similar changes observed in both treatment groups. No change in mean megakaryocyte size was apparent until day 2, when average size increased to approximately 130% of normal with both MGDF doses ($P = .001, 25 \ \mu g/kg; P =$.0004, 250 µg/kg, Mann-Whitney). Mean megakaryocyte size remained elevated on day 3 ($P = .001, 25 \ \mu g/kg; P =$.003, 250 µg/kg, Mann-Whitney), but by day 5 megakaryocyte size had returned to control values. Although average sizes tended to be smaller than control values on days 6-7 in mice treated with 25 μ g/kg MGDF, and on days 6 through 9 in mice treated with 250 μ g/kg MGDF ($P \ge .02$, Mann-Whitney, both doses), these values were associated with a P value > .004, which we selected for our significance level.

To determine if the increase in mean megakaryocyte size was related to the increase in megakaryocyte ploidy, megakaryocyte size was measured within each ploidy group (Fig 5). As shown, the average size of megakaryocytes increased, with increasing ploidy (Fig 5A and B). Although mean megakaryocyte size was elevated on day 2 with both doses of MGDF (see inset of Fig 5A and B), there was no change in the size of the megakaryocytes within each ploidy group; rather, the increase in mean megakaryocyte size observed on day 2 is a reflection of the modal ploidy shift from 16N to 32N observed with both doses of MGDF (Fig 2). As the



Fig 4. Effect of a single intravenous injection of rmMGDF on average size of polyploid megakaryocytes. The mean megakaryocyte size of 8N-128N cells was significantly increased from days 2 to 4 in mice treated with 25 μ g/kg of MGDF, and on days 2 and 3 in mice treated with 250 μ g/kg of MGDF. Each data point represents the mean \pm SEM of megakaryocyte size (8N-128N cells); for the 25- μ g/kg dose, n = 4-10 mice per MGDF group and n = 13 for controls and for the 250- μ g/kg dose, n = 5-9 mice per MGDF group and n = 20 for controls. Data from control mice were pooled to represent the day 0 data point.

modal ploidy returned to 16N on day 7, mean megakaryocyte size also returned to control values.

Megakaryocyte ultrastructure. Megakaryocyte ultrastructure was examined on day 4 (Fig 6), at the peak of the increased frequency of polyploid megakaryocytes (Fig 3B). BM from mice administered 1% NMS (Fig 6a), 25 μ g/kg MGDF (not shown), or 250 μ g/kg MGDF (Fig 6b) was examined by transmission electron microscopy. The ultrastructure of the megakaryocyte cytoplasm was normal in both groups of MGDF-treated mice. Although the increase in megakaryocyte size of MGDF-treated animals was apparent on day 4 (Fig 6b), the cytoplasmic distribution of the demarcation membrane system (DMS), α -granules, and other organelles was similar to that of the NMS-treated animals (Fig 6a).

DISCUSSION

Preclinical studies^{6-8,20} and early data from phase I trials⁴⁹⁻⁵¹ clearly indicate that recombinant thrombopoietin will prove useful in the clinic to ameliorate thrombocytopenia, especially that associated with chemotherapy.^{6,20,52} In our preliminary experiments⁵³ we noted that a single intravenous injection of PEG-rmMGDF was just as effective at elevating the platelet count threefold to fivefold of normal, as the multiple injection schedules used in these preclinical studies.⁶⁻⁸ Therefore, the aim of the present study was to determine the mechanism by which c*-mpl* ligand alters megakaryocytopoiesis to induce an increase in platelet production. To achieve this aim, we analyzed BM frequency of both the megakaryocyte precursor and the polyploid population, megakaryocyte DNA content, and megakaryocyte size at frequent intervals for 2 weeks after a single injection of MGDF to mice.

Our results show that a single injection of PEG-rmMGDF



Fig 5. Effect of rmMGDF on megakaryocyte size within individual ploidy classes in mice treated with $25-\mu g/kg$ (A) or $250-\mu g/kg$ (B) dose. MGDF causes a significant increase in mean megakaryocyte size (see inset) on day 2, with injection of $25 \mu g/kg$ (P = .001, Mann-Whitney) or $250 \mu g/kg$ (P = .004, Mann-Whitney) MGDF, with little change in the size of megakaryocytes within individual ploidy classes. The increase in mean megakaryocyte size results from an increase in the relative frequency of large polyploid cells. On day 2, 32N is the modal DNA class, while by day 7 16N is once again the normal modal class. Each data point represents the mean \pm SEM of megakaryocyte size. For the $25-\mu g/kg$ dose, n = 13 for the control and n = 5 on days 2 and 7. For the $250-\mu g/kg$ dose, n = 20 for the control, and n = 5 on day 2 and n = 8 on day 7.

 $(25 \ \mu g/kg \text{ or } 250 \ \mu g/kg)$ is able to substantially elevate megakaryocyte frequency and cause a marked shift in modal DNA content, which is accompanied by an increase in mean megakaryocyte size. The implication of these findings is that MGDF is capable of influencing both megakaryocytic proliferation and differentiation, a property that the classically defined thrombopoietin was thought to lack.^{54,55}

Our data clearly indicate that MGDF acts on a proliferative megakaryocytic 2N precursor, and the degree of expansion of this compartment is dose dependent. Although 25 $\mu g/\text{kg}$ of MGDF was able to expand the 2N/4N population fivefold, the higher dose of MGDF increased this population to 10-fold of normal. The greater expansion observed with 250 $\mu g/\text{kg}$ of MGDF translated to a sustained increase in the frequency of polyploid megakaryocytes from days 3 to 14. In contrast, increased frequency of polyploid megakaryocytes was of only 3 days duration with the 25 $\mu g/\text{kg}$ dose (days 3-5).

The exact nature of the 2N precursor population stimulated by MGDF in our studies is unknown. The antigen to which the 4A5 antibody is directed has been characterized as a thrombin-sensitive 74-kD glycoprotein present on murine megakaryocytes and platelets.⁵⁶ Whether this antibody is capable of binding and labeling the CFU-Meg, or is restricted to only the transitional small acetylcholinesterase positive (SACHE⁺) cells,⁵⁷ has not been determined. Our studies indicate that 48 hours were required to see an increase in the frequency of the 2N population, and the timing was independent of the dose given. However, the 2N population must have a short transition to the endomitotic compartment, as the increase in frequency of polyploid cells was observed only 24 hours later, on day 3. Therefore, the data suggest that a relatively late megakaryocyte progenitor (CFU-Meg) and the population of SACHE⁺ cells capable of cell division⁵⁷ are a target for MGDF. Similar conclusions were reached from in vitro studies using isolated human marrow progenitors,^{15,58} showing that a subpopulation of megakaryocyte progenitors (CD34⁺, CD41⁺ cells) expressed the receptor, c-mpl,⁵⁸ and may be the main target cells for thrombopoietin.¹⁵ These cells were shown to have limited capacity for cell division, usually generating colonies of small numbers of megakaryocytes.¹⁵ Furthermore, mice genetically engineered to be deficient in the thrombopoietin receptor (c- $mpl^{-/-}$), showed a greater deficiency in the more mature committed CFU-Meg of limited proliferative potential than in less mature megakaryocyte progenitors.⁵⁹ All these data suggest that relatively late megakaryocyte precursors are acutely responsive to changes in thrombopoietin levels and may play a pivotal role in accelerating megakaryocytopoiesis when there is an increased platelet demand.

A second major effect of MGDF is the profound stimulation of megakaryocyte endomitosis. The kinetics, although perhaps not the magnitude of stimulation, were similar to that observed in animals made acutely thrombocytopenic.^{60,61} As early as 12 hours after MGDF administration, a marked increase in the proportion of 64N and 128N cells was seen. Interestingly, the relative frequency of 32N cells, remained essentially unchanged. The increase in frequency of 64N and 128N cells must have resulted from stimulation of lower ploidy megakaryocytes (8N, 16N, 32N) to undergo a least one to two extra rounds of endomitosis within 12 hours. Given the steady-state cell-cycle time for rodent megakaryocytes of 10 hours,⁶² the data suggest that MGDF was able to shorten the cell cycle time for endomitotic megakaryocytes. An accelerated rate of megakaryocyte maturation has been reported in animals recovering from acute thrombocytopenia, where endogenous levels of thrombopoietin would be expected to be high.⁶³ The maximal shift in megakaryocyte ploidy was observed at 3 days, where 64N was the modal polyploid class and nearly 50% of all megakaryocytes had a ploidy value of 64N or greater, compared with only 3% in control marrow.

Accompanying the increase in megakaryocyte ploidy was an increase in mean megakaryocyte size. There was no evidence of any increase in megakaryocyte size within a specific ploidy class. Rather, the increase in frequency of high ploidy megakaryocytes (which were always larger in size) produced the increase in mean megakaryocyte size. Mean megakaryocyte size was increased on days 2 and 3, when the modal megakaryocyte ploidy was either 32N or 64N. By day 5, when the modal ploidy had returned to the

dms dms

Fig 6. Transmission electron micrographs of BM megakaryocytes from a mouse injected with 1% NMS (a) and a mouse injected with 250 μ g/kg rmMGDF (b). Although considerably larger in size than cells from control animals, the megakaryocytes from MGDF-treated animals contain normally distributed organelles within their cytoplasm, including the demarcation membrane system. Nu, nucleus; dms, demarcation membrane system. Original magnification × 4,000.

normal value of 16N, megakaryocyte size also returned to control values.

Our electron microscopic analysis of megakaryocyte morphology showed that MGDF promoted the development of ultrastructurally normal and mature megakaryocytes. We did not observe the maturational defects reported for megakaryocytes generated in culture with thrombopoietin.¹⁵ The most likely explanation for this aberrant megakaryocyte morphology in vitro is an insufficient microenvironment. Variation in exposure and clearance of MGDF may also contribute to the morphologic differences in megakaryocytes observed in vitro versus in vivo.

It has long been hypothesized that the number of platelets in circulation exercise feedback control on megakaryocytopoiesis, including regulation of megakaryocyte DNA content and size.^{60,61,64-66} Our data show that polyploidization was reduced between days 6 and 9 with 25 μ g/kg of MGDF and days 6 and 10 with 250 μ g/kg of MGDF. In studies reported elsewhere, we showed that a single injection of 25 μ g/kg or 250 μ g/kg MGDF raised the platelet count to threefold or fivefold on day 5.⁵³ Therefore, the longer duration of lowered ploidy in mice treated with 250 μ g/kg of MGDF was associated with the more pronounced thrombocytosis, and could be interpreted as the role of platelets in this regulatory process. However, at the same time, megakaryocyte number was also higher in mice treated with 250 μ g/kg MGDF and increased megakaryocyte frequency may alternatively downregulate polyploidy formation.

A mechanism whereby circulating platelets may affect feedback regulation of megakaryocytopoiesis recently has been proposed.^{4,41,67} In vivo production of thrombopoietin by the liver (primary site) and the kidney (secondarily) is hypothesized to be constitutive. In this proposed model, changes in the endogenous level of circulating thrombopoietin reflect the degree of binding of thrombopoietin to platelets.41 Megakaryocytes also bind thrombopoietin,68 and therefore megakaryocyte mass also may be important in modulating the circulating thrombopoietin levels.⁶⁹ Elevation of either platelet or megakaryocyte mass would be expected to decrease plasma thrombopoietin below the level necessary to sustain basal megakaryocyte differentiation. Therefore, the decrease in polyploidization we observed after the increase in megakaryocyte and platelet mass was most likely the result of lowered endogenous thrombopoietin levels in these mice. Support for this interpretation is provided by studies in mice deficient in thrombopoietin (TPO^{-/-}), where the modal ploidy class is decreased to 8N and the megakaryocytes are smaller in size.⁷⁰

In contrast to megakaryocyte maturation, no evidence for downregulation of megakaryocyte frequency is apparent after MGDF administration. This result is reminiscent of the response observed with 5-fluorouracil administration, where megakaryocyte ploidy and size were subject to different feedback regulatory mechanisms than proliferation.³⁵ These findings imply that megakaryocyte maturation may be more dependent than megakaryocyte precursor proliferation on thrombopoietin.

In our studies we found that a $25-\mu g/kg$ dose of MGDF was sufficient to maximally stimulate megakaryocyte ploidization and size. In contrast, stimulation of megakaryocyte proliferation was dependent on the dose we administered; the higher dose of MGDF gave a greater expansion of the 2N/4N megakaryocytic population. One interpretation is that less thrombopoietin is needed to induce ploidization and increase cell size than to stimulate proliferation by megakaryocyte precursors. However, we also observed that when less circulating thrombopoietin was presumably available (because of the increase in megakaryocyte and platelet mass), ploidization, but not frequency, was reduced. This paradox may be explained by location of megakaryocytes versus their precursors in the BM, and their accessibility to thrombopoietin. Mature megakaryocytes are known to lie adjacent to the BM sinus endothelium⁷¹⁻⁷³ and presumably have the most immediate access to circulating thrombopoietin. Thus, even at the lower dose of MGDF, megakaryocytes obviously had sufficient thrombopoietin binding to maximally stimulate ploidy and size. However, megakaryocyte precursors⁷³ are located distal to the sinus endothelium, and the effect of injected MGDF may be limited by its rate of diffusion from the vascular sinusoid to their distal location. Hence, a higher dose of MGDF was needed to penetrate the marrow and induce the greater degree of precursor proliferation. Therefore, the parasinusoidal location of mature megakaryocytes⁷² makes them more susceptible to variations in circulating thrombopoietin levels than megakaryocyte precursors. Megakaryocyte number, unlike ploidy, did not decrease below control values on days 6 to 10 (Figs 2 and 3), when the thrombopoietin levels in the circulation were expected to be low. Because the megakaryocyte precursors are less reliant on circulating levels of thrombopoietin, they may be sustained by the low constitutive thrombopoietin production by marrow stromal cells.19,74

In summary, a single injection of PEG-rmMGDF significantly augments the proliferation of late megakaryocyte precursors and markedly stimulates megakaryocyte maturation. Although expansion of the proliferating 2N/4N cells appeared dependent on the dose of MGDF we administered, both 25- μ g/kg and 250- μ g/kg doses of MGDF were able to maximally enhance ploidization and cell size.

ACKNOWLEDGMENT

The authors acknowledge the technical expertise provided by Dr Richard Ashmun and Sam Lucas for flow cytometric analysis of megakaryocyte DNA distributions. We also thank Amgen Inc for generously supplying PEG-rmMGDF.

REFERENCES

1. De Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W, Oles KJ, Hultgren B, Solberg LAJ, Goeddel DV, Eaton DL: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 369:533, 1994

2. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mattewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, O'Hara PJ, Hagen FS, Roth GJ, Foster DC: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production *in vivo*. Nature 369:565, 1994

3. Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, Horie K, Kokubo A, Kudo Y, Maeda E, Kobayashi K, Ohashi H, Ozawa T, Inoue H, Kawamura K, Miyazaki H: Purification and characterization of thrombopoietin. J Biochem 118:229, 1995

4. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 91:11104, 1994

5. Bartley TD, Bogenberger J, Hunt P, Li Y, Lu HS, Martin F, Chang M, Samal B, Nichol JL, Swift S, Johnson MJ, Hsu R, Parker VP, Suggs S, Skrine JD, Merewether LA, Clogston C, Hsu E, Hokom MM, Hornkohl A, Choi E, Pangelinan M, Sun Y, Mar V, McNinch J, Simonet L, Jacobsen F, Xie C, Shutter J, Chute H, Basu R, Selander L, Trollinger D, Sieu L, Padilla D, Trail G, Elliott G, Izumi R, Covey T, Crouse J, Garcia A, Xu W, Del Castillo J, Biron J, Cole S, Hu MC, Pacifici R, Ponting I, Saris C, Wen D, Yung YP, Lin H, Bosselman RA: Identification and cloning of a megakaryocyte 832

growth and development factor that is a ligand for the cytokine receptor mpl. Cell 77:1117, 1994

6. Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T, Wilson J, Steinbrink R, Hecht R, Winters D, Boone T, Hunt P: Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 86:4486, 1995

7. Farese AM, Hunt P, Boone T, MacVittie TJ: Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal and nonhuman primates. Blood 86:54, 1995

8. Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB: Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 87:1833, 1996

9. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC: Promotion of megakaryocyte progenitor expansion and differentiation by c-Mpl ligand thrombopoietin. Nature 369:568, 1994

10. Broudy VC, Lin NL, Kaushansky K: Thrombopoietin (*c-mpl* ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85:1719, 1995

11. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W: c-mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 369:571, 1994

12. Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger J, Skrine JD, Knudten A, Chen J, Trail G, Sleeman L, Cole S, Grampp G, Hunt P: Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 95:2973, 1995

13. Banu N, Wang J, Deng B, Groopman JE, Avraham H: Modulation of megakaryocytopoiesis by thrombopoietin: The c-Mpl ligand. Blood 86:1331, 1995

14. Zeigler FC, De Sauvage FJ, Widmer HR, Keller GA, Donahue C, Schreiber RD, Malloy B, Hass P, Eaton D, Matthews W: In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood 84:4045, 1994

15. Debili N, Wendling F, Katz A, Guichard J, Breton-Gorius J, Hunt P, Vainchenker W: The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 86:2516, 1995

16. Hunt P, Li Y, Nichol JL, Hokom MM, Bogenberger JM, Swift SE, Skrine JD, Hornkohl AC, Lu H, Clogston C, Merewether LA, Johnson MJ, Parker V, Knudten A, Farese A, Hsu RY, Garcia A, Stead R, Bosselman RA, Bartley TD: Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 86:540, 1995

17. Murray LJ, Mandich D, Bruno E, DiGiusto RK, Fu WC, Sutherland DR, Hoffman R, Tsukamoto A: Fetal bone marrow CD34⁺CD41⁺ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells. Exp Hematol 24:236, 1996

18. Choi ES, Hokom M, Bartley T, Li YS, Ohashi H, Kato T, Nichol JL, Skrine J, Knudten A, Chen J, Hornkohl A, Grampp G, Sleeman L, Cole S, Trail G, Hunt P: Recombinant human megakaryocyte growth and development factor (rHuMGDF), a ligand for c-Mpl, produces functional platelets in vitro. Stem Cells 13:317, 1995 19. Nagahisa H, Nagata Y, Ohnuki T, Osada M, Nagasawa T, Abe T, Todokoro K: Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood 87:1309, 1996

20. Ulich TR, Del Castillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger J, Sun D, Samal B, Shimamoto G, Lee R, Steinbrink R, Boone T, Sheridan WT, Hunt P: Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 86:971, 1995

21. Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK: Effects of treatment with MGDF and G-CSF on the acceleration of simultaneous neutrophil and platelet recovery after bone marrow transplant in mice. Blood 86:227a, 1995 (abstr, suppl 1)

22. Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK: Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood 88:366, 1996

23. Fibbe WE, Heemskerk DPM, Laterveer L, Pruijt JFM, Foster D, Kaushansky K, Willemze R: Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 86:3308, 1995

24. Neelis KJ, Wognum AW, Eaton D, Thomas R, Wagemaker G: Preclinical evaluation of thrombopoietin in rhesus monkeys. Blood 86:256a, 1995 (abstr, suppl 1)

25. Patchen ML, MacVitte TJ, Williams JL, Schwartz GN, Souza LM: Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery form radiation-induced hematopoietic depression. Blood 77:472, 1991

26. Monroy RL, Davis TA, Donahue RE, MacVitte TJ: In vivo stimulation of platelet production in a primate model using IL-1 and IL-3. Exp Hematol 19:629, 1991

27. Patchen ML, Fischer R, MacVitte TJ: Effect of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia. Exp Hematol 21:338, 1993

28. Levine RF, Fedorko ME: Isolation of intact megakaryocytes from guinea pig femoral marrow. Successful harvest made possible with inhibitors of platelet aggregation; enrichment achieved with a two-step separation technique. J Cell Biol 69:159, 1976

29. Burstein SA, Friese P, Downs T, Mei RL: Characteristics of a novel rat anti-mouse platelet monoclonal antibody: Application to studies of megakaryocytes. Exp Hematol 20:1170, 1992

30. Krishan A: Rapid flow cytometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66:188, 1975

31. Jackson CW, Brown LK, Somerville BC, Lyles SA, Look AT: Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions. Blood 63:768, 1984

32. McDonald TP, Jackson CW: Thrombopoietin derived form human embryonic kidney cells stimulates an increase in DNA content of murine megakaryocytes in vivo. Exp Hematol 18:758, 1990

33. Stenberg PE, Levin J, Baker G, Mok Y, Corash L: Neuraminidase-induced thrombocytopenia in mice: Effects on thrombopoiesis. J Cell Physiol 147:7, 1991

34. Jackson CW, Steward SA, Ashmun RA, McDonald TP: Megakaryocytopoiesis and platelet production are stimulated during late pregnancy and early postpartum in the rat. Blood 79:1672, 1992

35. Chenaille PJ, Steward SA, Ashmun RA, Jackson CW: Prolonged thrombocytosis in mice after 5-fluorouracil results from failure to down-regulate megakaryocyte concentration. An experimental model that dissociates regulation of megakaryocyte size and DNA content from megakaryocyte concentration. Blood 76:508, 1990

36. Corash L, Levin J, Mo KY, Baker G, McDowell J: Measure-

ment of megakaryocyte frequency and ploidy distribution in unfractionated murine bone marrow. Exp Hematol 17:278, 1989

37. Corash L, Chen HY, Levin J, Baker G, Lu H, Mok Y: Regulation of thrombopoiesis: Effects of the degree of thrombocytopenia on megakaryocyte ploidy and platelet volume. Blood 70:177, 1987

38. Corash L, Levin J: The relationship between megakaryocyte ploidy and platelet volume in normal and thrombocytopenic C3H mice. Exp Hematol 18:985, 1990

39. Arriaga M, South K, Cohen JL, Mazur EM: Interrelationship between mitosis and endomitosis in cultures of human megakaryocyte progenitor cells. Blood 69:486, 1987

40. Kuter DJ, Rosenberg RD: Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 5:1464, 1994

41. Kuter DJ, Rosenberg RD: The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 85:2720, 1995

42. Anderson TW: An Introduction to Multivariate Analysis. New York, NY, Wiley, 1984

43. Good P: Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York, NY, Springer-Verlag, 1994

44. Agresti A, Wackerly D, Boyett JM: Exact conditional tests for cross-classifications: Approximation of attained significance levels. Psychometrika 44:75, 1979

45. Ryan BF, Joiner BL, Ryan TA Jr: MINITAB Handbook. MINITAB Statistical Software, Boston, MA, MINITAB, Inc, PWS-KENT, 1985

46. Seber GAF: Linear Regression Analysis. New York, NY, Wiley, 1977

47. Conover WJ: Practical Nonparametric Statistics. New York, NY, Wiley, 1980

48. StatXact: Statistical Software for Exact Nonparametric Inference. User Manual. Cambridge, MA, CYTEL Software Corp, 1995

49. Basser R, Clarke K, Fox R, Green M, Cebon J, Marty J, Menchaca D, Tomita D, Begley G: Randomized, double-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (peg-rHuMGDF) administered to patients with advanced cancer before and after chemotherapy—Early results. Blood 86:1013, 1995 (abstr, suppl 1)

50. Begley G, Basser R, Clarke K, Rasko J, Green M, Grigg A, Cebon J, Marty J, Menchaca D, Tomita D, Fox R: Randomised, double-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced ovarian cancer after chemotherapy. Proc Annu Meet Am Soc Clin Oncol 15:271, 1996 (abstr)

51. Fannucchi M, Glaspy J, Crawford J, Ozer H, Figlin R, Tomita D, Menchaca D, Harker LA: Safety and biologic effects of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) in lung cancer patients receiving carboplatin and paclitaxel: Randomized, placebo-controlled phase I study. Proc Annu Meet Am Soc Clin Oncol 15:271, 1996 (abstr)

52. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC: Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 24:265, 1996

53. Daw NC, Arnold JT, White MM, Stenberg PE, Jackson CW: Regulation of thrombopoiesis: In vivo response to a single injection of murine, PEG-megakaryocyte growth and development factor. Blood 86:897a, 1995 (abstr, suppl 1)

54. Levin J, Levin FC, Hull DF, Penington DG: The effects of thrombopoietin on megakaryocyte-CFC, megakaryocytes, and

thrombopoiesis: With studies of ploidy and platelet size. Blood 60:989, 1982

55. Williams NT, Eger RR, Jackson HM, Nelson DJ: Two-factor requirement for murine megakaryocyte colony formation. J Cell Physiol 110:101, 1982

56. Takada K, Saito M, Kaneko H, Iizuka K, Kokai Y, Fujimoto J: Novel monoclonal antibody reactive with thrombin-sensitive 74-kDa glycoproteins present on platelets and megakaryocytes both from mouse and rat. Hybridoma 14:361, 1995

57. Long MW, Williams NT, Ebbe S: Immature megakaryocytes in the mouse: Physical characteristics, cell cycle status, and in vitro responsiveness to thrombopoietic stimulatory factor. Blood 59:569, 1982

58. Debili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, Schooley K, Methia N, Charon M, Nador R, Bettaieb A, Vainchenker W: The mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 85:391, 1995

59. Alexander WS, Roberts AW, Nicola NA, Li R, Metcalf D: Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-mpl. Blood 87:2162, 1996

60. Odell TT, Murphy JR, Jackson CW: Stimulation of megakaryocytopoiesis by acute thrombocytopenia in rats. Blood 48:765, 1976

61. Penington DG, Olsen TE: Megakaryocytes in states of altered platelet production: Cell numbers, sizes and DNA content. Br J Haematol 18:447, 1970

62. Odell TT, Jackson CW, Reiter RS: Generation cycle of rat megakaryocytes. Exp Cell Res 53:321, 1968

63. Ebbe S, Stohlman FJ, Donovan J, Overcash J: Megakaryocyte maturation rate in thrombocytopenic rats. Blood 32:787, 1968

64. Odell TT, Jackson CW, Reiter RS: Depression of the megakaryocyte-platelet system in rats by transfusion of platelets. Acta Haematol 38:34, 1967

65. Harker LA: Kinetics of thrombopoiesis. J Clin Invest 47:458, 1968

66. Ebbe S: Megakaryocytopoiesis, in Gordon AS (ed): Regulation of Hematopoiesis. New York, NY, Appleton-Century-Crofts, 1970, p 1587

67. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, De Sauvage FJ: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87:2154, 1996

68. Shivdasani RA: Molecular regulation of platelet production. Stem Cells 14:112, 1996 (suppl 1)

69. Emmons RVB, Ried DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87:4068, 1996

70. De Sauvage FJ, Carver-Moore K, Luoh SM, Ryan A, Dowd M, Eaton DL, Moore MW: Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 183:651, 1996

71. Tavassoli M, Aoki M: Localization of megakaryocytes in the bone marrow. Blood Cells 15:3, 1989

72. Lichtman MA, Chamberlain JK, Simon W, Santillo PA: Parasinusoidal location of megakaryocytes in marrow: A determinant of platelet release. Am J Hematol 4:303, 1978

73. Young KM: Localization of megakaryocytes in the bone marrow. Blood Cells 15:15, 1989

74. McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K: Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 86:3668, 1995